A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of resO™ Bone and Joint Support Postbiotic on Physical Function, Pain Interference, and Mobility in Adults With Joint Discomfort

NCT07602426 | Active Not Recruiting

• 1 other identifier: ABL-032504
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

This randomized, double-blind, placebo-controlled study evaluates the effects of resO™ Bone and Joint Support Postbiotic on physical function, pain interference, mobility, and recovery in adults aged 18-75 years experiencing joint discomfort, stiffness, or reduced mobility. Participants will be randomized to receive either resO™ or placebo for 4 weeks. Outcomes will be assessed using validated patient-reported outcome measures, including PROMIS Physical Function, PROMIS Pain Interference, Duke Activity Status Index (DASI), International Physical Activity Questionnaire-Short Form (IPAQ-SF), and pain numeric rating scales. The primary objective is to evaluate whether resO™ improves physical function and reduces pain interference compared with placebo.

Conditions

Joint Discomfort; Musculoskeletal Pain; Mobility Limitation

Keywords

Mobility Pain Interference; Physical Function; Postbiotic; Musculoskeletal Recovery; Nutraceutical; PROMIS; Mobility Support; Joint Health

Outcome Measures

Primary Outcomes (3)

• Change From Baseline to Week 4 in PROMIS Physical Function T-score

  PROMIS Physical Function Adult Short Form is a validated patient-reported outcome measure assessing physical functioning including walking, climbing stairs, bending, and carrying objects. Scores are standardized as T-scores with a population mean of 50 and standard deviation of 10. Higher scores indicate better physical function.

  Baseline and Week 4

• Changes in gut microbiota composition associated with bone health

  8 weeks

• Change From Baseline to Week 4 in PROMIS Pain Interference T-score

  PROMIS Pain Interference Adult Short Form is a validated patient-reported outcome measure assessing the extent to which pain interferes with daily activities, social participation, and quality of life. Scores are standardized as T-scores with a population mean of 50 and standard deviation of 10. Higher scores indicate greater pain interference.

  Baseline and Week 4

Secondary Outcomes (3)

• Change From Baseline to Week 4 in Pain Intensity Numeric Rating Scale (NRS) Score

  Baseline, weekly through Week 4, and Week 4

• Change From Baseline to Week 4 in Duke Activity Status Index (DASI) Score

  Baseline and Week 4

• Change From Baseline to Week 4 in International Physical Activity Questionnaire-Short Form (IPAQ-SF) MET-minutes/week

  Baseline and Week 4

Study Arms (2)

Placebo

PLACEBO COMPARATOR

Other: Placebo

Supplement

EXPERIMENTAL

Dietary Supplement: Supplement

Interventions

Placebo OTHER

Inactivated supplement

Placebo

Supplement DIETARY_SUPPLEMENT

Active supplement

Supplement

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Provide voluntary signed informed consent Adults aged 18-75 years Self-reported joint discomfort, stiffness, or reduced mobility affecting daily activities In generally good health based on self-reported medical history Agree to maintain stable diet, exercise, and lifestyle patterns throughout the study Able and willing to comply with study procedures and electronic questionnaires Access to smartphone, tablet, or computer with internet access

You may not qualify if:

• Chronic inflammatory or autoimmune joint disease requiring immunosuppressive or biologic therapy Recent joint surgery or significant musculoskeletal injury within the past 3 months Current unstable use of prescription medications intended for joint pain or inflammation Regular use of joint-targeting supplements that cannot be discontinued prior to participation Known allergy or intolerance to study product ingredients Participation in another investigational study within the past 30 days Pregnant, planning pregnancy, or breastfeeding Significant uncontrolled medical condition that may interfere with study participation or interpretation of results Inability or unwillingness to comply with study procedures

Sponsors & Collaborators

• Able Biolabs, LLC: lead

Study Sites (1)

Able Biolabs LLC

Dallas, Texas, 75247, United States

Location

MeSH Terms

Conditions

Musculoskeletal Pain; Mobility Limitation

Interventions

Dietary Supplements

Condition Hierarchy (Ancestors)

Muscular Diseases; Musculoskeletal Diseases; Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Food; Diet, Food, and Nutrition; Physiological Phenomena; Food and Beverages

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 29, 2026
• First Posted: May 22, 2026
• Study Start: April 13, 2026
• Primary Completion: May 15, 2026
• Study Completion (Estimated): May 31, 2026
• Last Updated: May 22, 2026

Record last verified: 2026-05

Locations

US (1)